Compare · IDXX vs MYMD
IDXX vs MYMD
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and MyMD Pharmaceuticals Inc. (MYMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and MYMD operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX carries a market cap of $54.38B.
- IDXX has hit the wire 9 times in the past 4 weeks while MYMD has been quiet.
- IDXX has more recent analyst coverage (25 ratings vs 0 for MYMD).
- Company
- IDEXX Laboratories Inc.
- MyMD Pharmaceuticals Inc.
- Price
- -
- -
- Market cap
- $54.38B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- 2014
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 0
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
MyMD Pharmaceuticals Inc.
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.
Latest IDXX
- Executive Vice President Fennell George exercised 1,749 shares at a strike of $171.38, increasing direct ownership by 17% to 12,182 units (SEC Form 4)
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 8,906 shares at a strike of $288.78 and sold $6,132,605 worth of shares (8,906 units at $688.59) (SEC Form 4)
- Executive Vice President Lane Michael sold $2,740,069 worth of shares (3,979 units at $688.64), decreasing direct ownership by 49% to 4,076 units (SEC Form 4)
- Executive Chair of the Board Mazelsky Jonathan Jay exercised 25,140 shares at a strike of $178.26 and sold $17,678,195 worth of shares (25,140 units at $703.19) (SEC Form 4)
- Director Junius Daniel M sold $844,888 worth of shares (1,200 units at $704.07), decreasing direct ownership by 34% to 2,361 units (SEC Form 4)
- Director Hooley Joseph L was granted 48 shares, increasing direct ownership by 15% to 373 units (SEC Form 4)
- SEC Form 10-Q filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IDEXX Laboratories Announces Third Quarter Results
- Goldman initiated coverage on IDEXX Labs with a new price target
Latest MYMD
- TNF Pharmaceuticals Trades Under New Ticker "TNFA"
- TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
- MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
- MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.
- SEC Form DEF 14A filed by MyMD Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Friscia Stephen
- Latest Key Hires & Board Changes In Cannabis Industry: Canopy Growth, Acreage And More
- MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-3 filed by MyMD Pharmaceuticals Inc.
- Amendment: MyMD Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement